SciSparc stock pops on Israeli ministry nod to start trial of Tourette Syndrome drug
gorodenkoff
- SciSparc (NASDAQ:SPRC) said it received approval from the Israeli Ministry of Health to conduct a phase 2b trial of its oral drug SCI-110 to treat adults with Tourette Syndrome (TS).
- TS is a disorder in which people cannot stop their body from making sudden twitches, movements or sounds (tics).
- The first clinical site to receive approval to carry out the study is Tel Aviv Sourasky Medical Center, in Tel Aviv, Israel.
- The company also plans to conduct the study in the U.S. and Germany.
- In the study, patients will receive either SCI-110 or a placebo. The main efficacy goal of the trial will be to evaluate tic severity change, according to the company.
- SPRC +6.67% to $0.77 premarket March 9